Adjuvant therapy for resectable NSCLC.

被引：0
|
作者：
Douillard, JY [1 ]
Delgado, FM [1 ]
Larriba, JL [1 ]
Rosell, R [1 ]
De Lena, M [1 ]
Rodrigues, J [1 ]
Carpagnano, F [1 ]
Danel, P [1 ]
Kolek, V [1 ]
Biville, F [1 ]
机构：
[1] IRPF, Boulogne, France
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P23
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [1] ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
    Sands, Jacob
    Mandrekar, Sumithra J.
    Oxnard, Geoffrey R.
    Kozono, David E.
    Hillman, Shauna L.
    Dahlberg, Suzanne Eleanor
    Sun, Zhuoxin
    Chaft, Jamie E.
    Govindan, Ramaswamy
    Gerber, David E.
    Gray, Jhanelle Elaine
    Malik, Shakun M.
    Mooney, Margaret M.
    Janne, Pasi A.
    Vokes, Everett E.
    Kelly, Karen
    Ramalingam, Suresh S.
    Stinchcombe, Tom
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Analysis of the prognostic value of the tumor immunologic profile in resectable NSCLC.
    Uso, Marta
    Jantus-Lewintre, Eloisa
    Sirera, Rafael
    Calabuig-Farinas, Silvia
    Blasco, Ana
    Guijarro, Ricardo
    Pastor, Enrique
    Camps, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
    Bogatsa, Evangelia
    Lazaridis, George
    Stivanaki, Chrysoula
    Timotheadou, Eleni
    [J]. CANCERS, 2024, 16 (09)
  • [4] Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
    Evans, Nathaniel R.
    Cowan, Scott
    Solomides, Charalambos
    Hooper, D. Craig
    Harshyne, Larry
    Lu-Yao, Grace L.
    Yang, Hushan
    Phan, Linda
    Poller, Dawn
    Leiby, Benjamin
    Werner-Wasik, Maria
    Lu, Bo
    Johnson, Jennifer Maria
    Axelrod, Rita Susan
    Argiris, Athanassios
    Zinner, Ralph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A meta-analysis of systematic lymph node dissection in resectable NSCLC.
    Yang, H
    Wu, Y
    Yang, X
    Chen, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 663S - 663S
  • [6] Neoadjuvant and Adjuvant Approaches in Surgically Resectable NSCLC
    Chaft, Jamie E.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (10) : 631 - 633
  • [7] Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
    Lee, Jiyun
    Cho, Jaeho
    Lee, Chang
    Lee, Chang Young
    Lee, Jin Gu
    Kim, Dae Joon
    Shim, Hyo Sup
    Lim, Sun Min
    Kim, Hye Ryun
    Cho, Byoung Chul
    Hong, Min Hee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.
    Pathak, Ranjan
    Hoag, Jessica R.
    Goldberg, Sarah B.
    Monsalve, Andres F.
    Resio, Benjamin
    Boffa, Daniel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Mutations in NSCLC.
    Holland, Aalaug
    Bruatugun, Odd Terje
    Nakken, Sigve
    Halvorsen, Ann Rita
    Sun, Jinchang
    Lorenz, Susanne
    Vodak, Daniel
    Myklebost, Ole
    Hovig, Eivind
    Moza-Zopoda, Leonardo A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Neoadjuvant chemo-immunotherapy increases tumor immune lymphocytes infiltration in resectable NSCLC.
    Li, Ziming
    Chen, Tianxiang
    Wen, Fengcai
    Zhang, Ding
    Chen, Yanan
    Zhao, Xiaochen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345